Genmab A/S (NASDAQ:GMAB) Shares Sold by Assetmark Inc.

Assetmark Inc. decreased its stake in Genmab A/S (NASDAQ:GMAB - Free Report) by 78.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 18,109 shares of the company's stock after selling 64,520 shares during the period. Assetmark Inc.'s holdings in Genmab A/S were worth $378,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Two Sigma Advisers LP lifted its position in shares of Genmab A/S by 84.1% during the 3rd quarter. Two Sigma Advisers LP now owns 615,100 shares of the company's stock valued at $14,996,000 after acquiring an additional 280,900 shares during the period. ABC Arbitrage SA purchased a new position in Genmab A/S in the 4th quarter valued at approximately $3,692,000. AIMZ Investment Advisors LLC purchased a new stake in Genmab A/S during the fourth quarter worth $3,525,000. Y Intercept Hong Kong Ltd boosted its position in Genmab A/S by 371.0% during the fourth quarter. Y Intercept Hong Kong Ltd now owns 73,696 shares of the company's stock worth $1,538,000 after purchasing an additional 58,048 shares in the last quarter. Finally, Natixis Advisors LLC grew its holdings in Genmab A/S by 29.8% in the third quarter. Natixis Advisors LLC now owns 206,563 shares of the company's stock valued at $5,036,000 after purchasing an additional 47,437 shares during the last quarter. Hedge funds and other institutional investors own 7.07% of the company's stock.

Genmab A/S Stock Down 0.2 %

Shares of Genmab A/S stock opened at $20.21 on Thursday. Genmab A/S has a fifty-two week low of $18.64 and a fifty-two week high of $31.88. The business's fifty day moving average is $21.28 and its two-hundred day moving average is $22.52. The firm has a market cap of $13.37 billion, a PE ratio of 11.61, a P/E/G ratio of 2.65 and a beta of 0.98.

Remove Ads

Genmab A/S (NASDAQ:GMAB - Get Free Report) last released its earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share for the quarter, topping the consensus estimate of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. Equities research analysts anticipate that Genmab A/S will post 1.45 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the stock. Leerink Partners upgraded shares of Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 price objective on the stock in a research report on Thursday, February 13th. Sanford C. Bernstein raised shares of Genmab A/S from a "strong sell" rating to a "hold" rating in a report on Friday, December 20th. Leerink Partnrs raised shares of Genmab A/S from a "hold" rating to a "strong-buy" rating in a research note on Thursday, February 13th. William Blair upgraded Genmab A/S from a "market perform" rating to an "outperform" rating in a research report on Tuesday. Finally, Truist Financial lowered their target price on Genmab A/S from $50.00 to $45.00 and set a "buy" rating on the stock in a report on Tuesday. Four research analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $41.33.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.